
S1 Episode 6: Non-Muscle Invasive Bladder Cancer Innovations
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Drs Cheryl Lee and Sima Porten discuss urinary biomarkers, enhanced cystoscopy, treatments on the horizon, and communication with team members from the cytopathology lab using the PARIS classification.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970416). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Paris System for Reporting Urinary Cytopathology https://paris.soc.wisc.edu/index.htm
Bladder Cancer Biomarkers: Optimal Utilization for Diagnosis and Recurrence https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/93133-bladder-cancer-biomarkers-optimal-utilization-for-diagnosis-and-recurrence-everyday-urology-full-text-article.html
Diagnostic Performance of Oncuria™, a Urinalysis Test for Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025333/
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer https://www.frontiersin.org/articles/10.3389/fimmu.2020.615091/full